<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984334</url>
  </required_header>
  <id_info>
    <org_study_id>NAL-OIC-01</org_study_id>
    <secondary_id>2009-009377-10</secondary_id>
    <nct_id>NCT00984334</nct_id>
  </id_info>
  <brief_title>Naloxone SR Capsules in Patients With Opioid Induced Constipation</brief_title>
  <official_title>A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability and Efficacy of Naloxone SR Capsules in Subjects With Constipation Due to Opioids, Taken for Persistent Non-Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S.L.A. Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>S.L.A. Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For many patients taking opioids for pain relief one of the most distressing side effects is
      constipation. Naloxone is effective in the reversal of the effects of opioids and is used
      following opioid overdose. If naloxone is given by mouth it would relieve the effects of
      constipation but as it goes into the blood stream very quickly, it would also reverse the
      effects of the opioid and therefore stop the pain relief. The aim of this study is to examine
      a slow release formulation of naloxone to see if is can reduce constipation without reducing
      the pain relieving effects of the opioid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Naloxone has been used for many years as an IV or IM injection for the reversal of opioid
      effects (following opioid overdose) and has been evaluated as an oral formulation to manage
      opioid-induced constipation. Immediate release oral naloxone preparations have however led to
      reversal of opioid effects and withdrawal. This has initiated the development of prolonged
      (slow release) naloxone preparations which prevent the systemic levels of naloxone reaching
      levels where the central opioid effects may be reversed. Naloxone has a high first pass
      metabolism (98%) and short half life (~1hr).

      The objectives of this trial are to identify the optimum dosage regime of Naloxone SR
      capsules based on tolerability level, to improve spontaneous bowel movement frequency, and
      relieve GI symptoms, in patients suffering with opioid induced constipation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Treatment Emergent Adverse Events on Single Dosing.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Incidence and severity of treatment emergent adverse events on single dosing.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Opioid Induced Constipation</condition>
  <arm_group>
    <arm_group_label>Capsules with no active drug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules once daily for three weeks then twice daily for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone SR 2.5 mg capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone SR 10mg capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone SR 20 mg capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone SR 5mg capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone SR 5 mg capsules</intervention_name>
    <arm_group_label>Naloxone SR 5mg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Capsules with no active drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone SR 10 mg capsules</intervention_name>
    <arm_group_label>Naloxone SR 10mg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone SR 20mg capsules</intervention_name>
    <arm_group_label>Naloxone SR 20 mg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone SR 2.5 mg capsules</intervention_name>
    <arm_group_label>Naloxone SR 2.5 mg capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects must give written informed consent

          -  Male or female subjects greater than 18 years of age

          -  Taking opioid full agonist therapy(oral or transdermal) for persistent non-cancer
             pain, for at least 4 weeks prior to baseline visit

          -  Subjects with at least a 3 week history of OIC prior to baseline; where bowel
             dysfunction is predominantly due to opioids and started following commencement of
             opioid therapy

          -  Subjects with &lt;3 SBMs a week and experiencing one or more bowel symptoms (incomplete
             evacuation, straining, hard/small pellets) for 25% or more of bowel movements during
             the screening period

          -  Subjects must be willing to discontinue all current laxative (constipation) therapy.
             Bisacodyl will be provided and taken as required

        Exclusion Criteria:

          -  Women of childbearing potential, unless surgically sterile or using adequate
             contraception (either IUD, oral or depot contraceptive, or barrier plus spermicide).
             Women using oral contraception must have started using it at least 2 months prior to
             enrolment

          -  Women who are pregnant or breastfeeding

          -  Symptoms suggestive of non-opioid related bowel dysfunction (e.g. IBS - intermittent
             constipation or diarrhoea) or have diarrhoea or loose stools in the 4 weeks prior to
             baseline

          -  History of chronic constipation prior to commencing opioid therapy

          -  Gastrointestinal disorders known to affect bowel transit, or contribute to bowel
             dysfunction (other than OIC)

          -  Chronic faecal incontinence

          -  Subjects who have a colostomy, ileostomy, or colectomy with ileorectal anastomosis

          -  Subjects with a history of neoplastic disease within 5 years (except for basal cell
             carcinoma or non-metastatic squamous cell carcinoma of the skin)

          -  Subjects taking opioids for the management of drug addiction Subjects who do not meet
             any of the following criteria regarding baseline medications. Analgesia (including
             opioids and NSAIDs) should be stable throughout the trial.

               -  Any baseline analgesia must have been administered at a stable dose for a minimum
                  of 4 weeks. If non-opioid analgesia recently discontinued, must have stopped at
                  least 4 weeks prior to baseline

               -  Laxatives (outside that allowed by the protocol) are not permitted; these agents
                  must have been discontinued at the screening visit.

               -  Use of drugs known to affect gut transit time (other than opioids) are not
                  permitted (see Section 6.9 for exceptions)

               -  Use of mixed agonist/antagonist, or partial agonist opioids are not permitted
                  (e.g. buprenorphine, pentazocine, cyclazocine, nalbuphine, nalorphine)

               -  Experimental agents must have been discontinued at least 8 weeks prior to
                  screening, or for a period equivalent to 5 half-lives (tÂ½) of the agent
                  (whichever is longer)

               -  Subjects with a history of clinically significant and/or persistent disorder
                  that, in the investigators opinion, may affect the clinical trial assessments

               -  Subjects with any laboratory tests considered clinically significant at
                  screening.

               -  Subjects not ambulatory i.e. bedridden or require use of a commode

               -  Subjects who will be unavailable for the duration of the trial, likely to be
                  non-compliant with the protocol, or who are felt to be unsuitable by the
                  Investigator for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Simpson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St James University Hospital, Leeds, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schmerzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schmerzzentrum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60311</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Tamm-Albert-Schroter-Uhmann</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Loewenstein-Hesselbarth</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionales Schmerzzentrum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Jame's Hospital Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich Hospital</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pain Management, York Hospital</name>
      <address>
        <city>York</city>
        <zip>LS14 6UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <results_first_submitted>November 7, 2013</results_first_submitted>
  <results_first_submitted_qc>November 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 27, 2013</results_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>opioid</keyword>
  <keyword>constipation</keyword>
  <keyword>Subjects taking opioids for chronic non-cancer pain, who</keyword>
  <keyword>experience symptoms of opioid induced constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Capsules With no Active Drug</title>
          <description>Placebo capsules once daily for three weeks then twice daily for three weeks.
Placebo :</description>
        </group>
        <group group_id="P2">
          <title>Naloxone SR 10mg Capsules</title>
          <description>Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 10 mg capsules :</description>
        </group>
        <group group_id="P3">
          <title>Naloxone SR 2.5 mg Capsules</title>
          <description>Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 2.5 mg capsules :</description>
        </group>
        <group group_id="P4">
          <title>Naloxone SR 20 mg Capsules</title>
          <description>Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 20mg capsules :</description>
        </group>
        <group group_id="P5">
          <title>Naloxone SR 5mg Capsules</title>
          <description>Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 5 mg capsules :</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Capsules With no Active Drug</title>
          <description>Placebo capsules once daily for three weeks then twice daily for three weeks.
Placebo :</description>
        </group>
        <group group_id="B2">
          <title>Naloxone SR 10mg Capsules</title>
          <description>Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 10 mg capsules :</description>
        </group>
        <group group_id="B3">
          <title>Naloxone SR 2.5 mg Capsules</title>
          <description>Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 2.5 mg capsules :</description>
        </group>
        <group group_id="B4">
          <title>Naloxone SR 20 mg Capsules</title>
          <description>Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 20mg capsules :</description>
        </group>
        <group group_id="B5">
          <title>Naloxone SR 5mg Capsules</title>
          <description>Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 5 mg capsules :</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="10.2"/>
                    <measurement group_id="B2" value="53.4" spread="15.7"/>
                    <measurement group_id="B3" value="50.6" spread="12.7"/>
                    <measurement group_id="B4" value="48.6" spread="8.6"/>
                    <measurement group_id="B5" value="60.5" spread="8.8"/>
                    <measurement group_id="B6" value="53.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Treatment Emergent Adverse Events on Single Dosing.</title>
        <description>Incidence and severity of treatment emergent adverse events on single dosing.</description>
        <time_frame>3 weeks</time_frame>
        <population>Intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Capsules With no Active Drug</title>
            <description>Placebo capsules once daily for three weeks then twice daily for three weeks.
Placebo :</description>
          </group>
          <group group_id="O2">
            <title>Naloxone SR 10mg Capsules</title>
            <description>Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 10 mg capsules :</description>
          </group>
          <group group_id="O3">
            <title>Naloxone SR 2.5 mg Capsules</title>
            <description>Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 2.5 mg capsules :</description>
          </group>
          <group group_id="O4">
            <title>Naloxone SR 20 mg Capsules</title>
            <description>Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 20mg capsules :</description>
          </group>
          <group group_id="O5">
            <title>Naloxone SR 5mg Capsules</title>
            <description>Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 5 mg capsules :</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Treatment Emergent Adverse Events on Single Dosing.</title>
          <description>Incidence and severity of treatment emergent adverse events on single dosing.</description>
          <population>Intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Capsules With no Active Drug</title>
          <description>Placebo capsules once daily for three weeks then twice daily for three weeks.
Placebo :</description>
        </group>
        <group group_id="E2">
          <title>Naloxone SR 10mg Capsules</title>
          <description>Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 10 mg capsules :</description>
        </group>
        <group group_id="E3">
          <title>Naloxone SR 2.5 mg Capsules</title>
          <description>Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 2.5 mg capsules :</description>
        </group>
        <group group_id="E4">
          <title>Naloxone SR 20 mg Capsules</title>
          <description>Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 20mg capsules :</description>
        </group>
        <group group_id="E5">
          <title>Naloxone SR 5mg Capsules</title>
          <description>Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
Naloxone SR 5 mg capsules :</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <description>panic attack during pre-treatment screening phase.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="25" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="14" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="10" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects per group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr C Jordan, Head of Clinical Operations</name_or_title>
      <organization>S.L.A. Pharma UK Ltd</organization>
      <phone>44 01923 681001</phone>
      <email>cjordan@slapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

